Nereid Therapeutics says its drug discovery platform is based on proprietary technologies aimed at precisely measuring, interrogating, and controlling phase separation in mammalian cells . . .
Set Phase Separation to Stun
Nereid Therapeutics translating biomolecular condensate research into new drugs with $50M Series A financing
Pioneering research in biomolecular condensates by Princeton University biophysicist Clifford P. Brangwynne, PhD, has included the development of novel tools such as Corelet, a rapid, light-activated tool for mapping local and global phase separation. Translating Brangwynne’s research into new drugs for diseases that include cancer and neurodegenerative disorders is the goal of Nereid Therapeutics, launched with $50 million in Series A financing. [Nereid Therapeutics]
